The final date of the CEEGOG meeting was set for December 13, 2019, which will be held in Prague at the Department of Obstetrics and Gynecology of the General University Hospital in Prague for one day. We will be happy to include proposals for new collaborative trials as suggested by you. Should you like to share some information on your projects and proposal studies with other CEEGOG members, kindly let us know by November 15.
All your colleagues and study coordinators are cordially welcome as well. We would like to ask for confirmation of your participation by October 15.
The invitation card and further details will be sent out in the near future.
We look forward to meeting with all of you at the scheduled CEEGOG meeting.
Pursuant to the the BYLAWS of CEEGOG, new leadership must be elected every 5 years.
As the time of first electoral term is over, the election of the new Chair, Vice-chair, Financial manager and Controller will be conducted at the forthcoming CEEGOG meeting.
In case you are interested in one of the positions mentioned above and/or want to nominate and recommend someone else, please send your CV and/ or nomination to the CEEGOG office by November 15. Thank you in advance.
CEEGOG representatives in ENGOT projects should be replaced after a certain period of time. Currently, position are open for new candidates in the Phase I/II group and in the GCA (Gyne Cancer Academy).
Phase I/II group aims at the development of a network of early phase trial centres and investigators within ENGOT to deliver early phase clinical trials with strong scientific rationale, and to develop novel trial designs that allow efficient assessment of new compounds and make it feasible to also investigate rare histological and molecular subtypes.
GCA- educative workshops aim at the training and development of the next generation of leaders in gynaecological oncology. The experienced physicians in gynecology oncology prepare programs and lead the disscussion. Topics targeted the effective clinical trial design and collaboration, implementation, conduct and analysis within the ENGOT framework. Participants are experienced investigators who are not yet fully in a position to lead cooperative groups but have the potential to adopt this role in the future.
The GCIG Spring meeting was held in Chicago on May 29-30, 2019. The CEEGOG Chairman represented CEEGOG at the meeting and introduced there the planned CEEGOG trial on the role of radical surgery and adjuvant treatment in the management of intermediate / high risk patients with early stage cervical cancer (Sedlis 2020).
The spring ENGOT meeting took place in Frankfurt am Main, on March 21-22.
The administrative meeting highlighted the following topics: mentoring, BREXIT and Sponsor/ legal representative in EU, trial budget, pharmacovigilance survey, sharing group resources, General Data Protection Regulation.
The ENGOT Chair, Antonio González Martín, gave update on the ongoing trials where he also informed on the CEEGOG trials: ABRAX, FERTISS and SENTIX. David Cibula update on the SOV09/VITALIA trial with dendritic cells in patients with advanced ovarian cancer (sponsor Sotio).
Discussions were held on the ENGOT strategic group, establishment of a trial support office, biobank project, and COST program. Antonio González Martín mentioned the new clinical trial section in the IJGC. ENGOT is going to prepare a list of trials that could be published there.
Voting on election of new chairs was conducted. Both Maren Keller from NOGGO for the operational group and Mansoor Raza Mirza for the medical doctors were approved unanimously.
As the center Institute of Oncology of Moldova was approved as a new CEEGOG member at the CEEGOG meeting held in November 2018, currently CEEGOG has centers in 13 countries, i.e. the Czech Republic, Slovakia, Poland, Slovenia, Ukraine, Hungary, Belarus, Georgia, Croatia, Macedonia, Serbia, Romania and the Republic Moldova. Welcome to collaboration!
On November 7-8, 2018, a meeting of representatives of the national trial groups was held in Amsterdam in the Netherlands. CEEGOG was represented by Vít Weinberger (UH Brno, Czech Republic) and the CEEGOG administrative manager Mrs. Ivana Nohová.
The Engot Admin meeting was focused on budgeting a clinical trial, ENGOT monitoring network, and sharing group resources. Roxana Albu from EORTC talked about the General Data Protection Regulation (GDPR).
The ENGOT Administrative meeting was followed by the ENGOT assembly meeting. Vít Weinberger updated other ENGOT group representatives on the FERTISS trial. On behalf of the CEEGOG Chair, Mansoor Raza Mirza from NSGO introduced the planned SOV09 trial for which CEEGOG had been designated as the Lead group. The 16 ENGOT groups expressed their preliminary interest in trial participation.
The main topic of the ENGOT assembly meeting involved trial activities and regular update on clinical trial research conducted under the ENGOT umbrella. Mansoor Raza Mirza reported about the ESGO council meeting held in Berlin on November 1-2. Antonio González Martín talked about the planned ENGOT conference which should expand awareness about the ENGOT mission and projects, and increase commitments of the investigators.
More information may be provided by the CEEGOG office on request.
The GCIG Autumn meeting was held on October 17-18, 2018, in Munich.
CEEGOG was represented by its Chairman, the administrative manager Mrs. Ivana Nohová, and by Dr. Volha Matylevich from the N.N. Alexandrov National Cancer Center of Belarus in Minsk. Since a Pathology Brainstorming Session was scheduled during the meeting, the pathologist Pavel Dundr from the Pathology Institute in Prague attended the Session. The Session focused on imaging techniques, molecular imaging, advances in digital pathology and artificial intelligence for primary diagnostics in gynaecological pathology, and its opporunities for use in clinical trials. The participants were informed on itegrating molecular markers into clinical trials, and the minimal pathology requirements in clinical trials. The discussion was centered around new imaging and pathology priorities in clinical research.
Page 1 of 4